Literature DB >> 28478511

Cataplexy and Its Mimics: Clinical Recognition and Management.

Sigrid Pillen1, Fabio Pizza2,3, Karlien Dhondt4, Thomas E Scammell5, Sebastiaan Overeem6,7.   

Abstract

OPINION STATEMENT: This review describes the diagnosis and management of cataplexy: attacks of bilateral loss of muscle tone, triggered by emotions and with preserved consciousness. Although cataplexy is rare, its recognition is important as in most cases, it leads to a diagnosis of narcolepsy, a disorder that still takes a median of 9 years to be diagnosed. The expression of cataplexy varies widely, from partial episodes affecting only the neck muscles to generalized attacks leading to falls. Moreover, childhood cataplexy differs from the presentation in adults, with a prominent facial involvement, already evident without clear emotional triggers ('cataplectic facies') and 'active' motor phenomena especially of the tongue and perioral muscles. Next to narcolepsy, cataplexy can sometimes be caused by other diseases, such as Niemann-Pick type C, Prader Willi Syndrome, or lesions in the hypothalamic or pontomedullary region. Cataplexy mimics include syncope, epilepsy, hyperekplexia, drop attacks and pseudocataplexy. They can be differentiated from cataplexy using thorough history taking, supplemented with (home)video recordings whenever possible. Childhood narcolepsy, with its profound facial hypotonia, can be confused with neuromuscular disorders, and the active motor phenomenona resemble those found in childhood movement disorders such as Sydenham's chorea. Currently, the diagnosis of cataplexy is made almost solely on clinical grounds, based on history taking and (home) videos. Cataplexy shows remarkable differences in childhood compared to adults, with profound facial hypotonia and complex active motor phenomena. Over time, these severe symptoms evolve to the milder adult phenotype, and this pattern is crucial to recognize when assessing the outcome of uncontrolled case series with potential treatments such as immunomodulation. Symptomatic treatment is possible with antidepressants and sodium oxybate. Importantly, management also needs to involve sleep hygiene advice, safety measures whenever applicable and guidance with regard to the social sequelae of cataplexy.

Entities:  

Keywords:  Cataplexy; Drop attacks; Narcolepsy; Pseudocataplexy; Sodium oxybate; Syncope

Year:  2017        PMID: 28478511     DOI: 10.1007/s11940-017-0459-0

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  102 in total

1.  Weak with laughter.

Authors:  S Overeem; G J Lammers; J G van Dijk
Journal:  Lancet       Date:  1999-09-04       Impact factor: 79.321

2.  Praxis-induced seizures misdiagnosed as cataplexy: a case report.

Authors:  Giuseppe Plazzi; Paolo Tinuper
Journal:  Mov Disord       Date:  2008-10-30       Impact factor: 10.338

3.  Epilepsy and cataplexy in Angelman syndrome. Genotype-phenotype correlations.

Authors:  Line Granild Bie Mertz; Rikke Christensen; Ida Vogel; Jens Michael Hertz; John R Østergaard
Journal:  Res Dev Disabil       Date:  2016-09

4.  Orexin neurons suppress narcolepsy via 2 distinct efferent pathways.

Authors:  Emi Hasegawa; Masashi Yanagisawa; Takeshi Sakurai; Michihiro Mieda
Journal:  J Clin Invest       Date:  2014-01-02       Impact factor: 14.808

5.  The number of hypothalamic hypocretin (orexin) neurons is not affected in Prader-Willi syndrome.

Authors:  Rolf Fronczek; Gert Jan Lammers; Rawien Balesar; Unga A Unmehopa; Dick F Swaab
Journal:  J Clin Endocrinol Metab       Date:  2005-06-28       Impact factor: 5.958

6.  Conditional ablation of orexin/hypocretin neurons: a new mouse model for the study of narcolepsy and orexin system function.

Authors:  Sawako Tabuchi; Tomomi Tsunematsu; Sarah W Black; Makoto Tominaga; Megumi Maruyama; Kazuyo Takagi; Yasuhiko Minokoshi; Takeshi Sakurai; Thomas S Kilduff; Akihiro Yamanaka
Journal:  J Neurosci       Date:  2014-05-07       Impact factor: 6.167

7.  Narcolepsy with cataplexy mimicry: the strange case of two sisters.

Authors:  Fabio Pizza; Stefano Vandi; Francesca Poli; Keivan Kaveh Moghadam; Christian Franceschini; Claudia Bellucci; Carlo Cipolli; Francesca Ingravallo; Giuliana Natalini; Emmanuel Mignot; Giuseppe Plazzi
Journal:  J Clin Sleep Med       Date:  2013-06-15       Impact factor: 4.062

8.  Fluvoxamine and clomipramine in the treatment of cataplexy.

Authors:  M Schachter; J D Parkes
Journal:  J Neurol Neurosurg Psychiatry       Date:  1980-02       Impact factor: 10.154

Review 9.  Management of Narcolepsy.

Authors:  Lucie Barateau; Régis Lopez; Yves Dauvilliers
Journal:  Curr Treat Options Neurol       Date:  2016-10       Impact factor: 3.598

10.  Early co-occurrence of a neurologic-psychiatric disease pattern in Niemann-Pick type C disease: a retrospective Swiss cohort study.

Authors:  Lucia Abela; Barbara Plecko; Antonella Palla; Patricie Burda; Jean-Marc Nuoffer; Diana Ballhausen; Marianne Rohrbach
Journal:  Orphanet J Rare Dis       Date:  2014-11-26       Impact factor: 4.123

View more
  10 in total

1.  Giving a voice to cataplectic experience: recollections from patients with narcolepsy type 1.

Authors:  Christian Franceschini; Chiara Fante; Maria Claudia Folli; Maria Filosa; Fabio Pizza; Elena Antelmi; Francesca Ingravallo; Giuseppe Plazzi
Journal:  J Clin Sleep Med       Date:  2020-04-15       Impact factor: 4.062

Review 2.  Diagnosis and management of sleep disorders in Prader-Willi syndrome.

Authors:  Jessica Duis; Lara C Pullen; Maria Picone; Norman Friedman; Stephen Hawkins; Elise Sannar; Anna C Pfalzer; Althea Robinson Shelton; Deepan Singh; Phyllis C Zee; Daniel G Glaze; Amee Revana
Journal:  J Clin Sleep Med       Date:  2022-06-01       Impact factor: 4.324

3.  Cataplexy and ataxia: red flags for the diagnosis of DNA methyltransferase 1 mutation.

Authors:  Emanuela Postiglione; Elena Antelmi; Fabio Pizza; Stefano Vandi; Chiara La Morgia; Valerio Carelli; Stefania Nassetti; Marco Seri; Giuseppe Plazzi
Journal:  J Clin Sleep Med       Date:  2019-12-06       Impact factor: 4.062

4.  Images: Facial cataplexy with demonstration of persistent eye movements.

Authors:  Logan Schneider; Jeffrey Ellenbogen
Journal:  J Clin Sleep Med       Date:  2019-11-26       Impact factor: 4.062

5.  Narcolepsy type 1 features across the life span: age impact on clinical and polysomnographic phenotype.

Authors:  Althea Lividini; Fabio Pizza; Marco Filardi; Stefano Vandi; Francesca Ingravallo; Elena Antelmi; Oliviero Bruni; Filomena Irene Ilaria Cosentino; Raffaele Ferri; Biancamaria Guarnieri; Sara Marelli; Luigi Ferini-Strambi; Andrea Romigi; Enrica Bonanni; Michelangelo Maestri; Michele Terzaghi; Raffaele Manni; Giuseppe Plazzi
Journal:  J Clin Sleep Med       Date:  2021-07-01       Impact factor: 4.324

Review 6.  Narcolepsy type 1: what have we learned from genetics?

Authors:  Hanna M Ollila
Journal:  Sleep       Date:  2020-11-12       Impact factor: 5.849

Review 7.  Narcolepsy Presentation in Diverse Populations: an Update.

Authors:  Karen Spruyt
Journal:  Curr Sleep Med Rep       Date:  2020-11-25

Review 8.  A practical guide to the pharmacological and behavioral therapy of Narcolepsy.

Authors:  Christian Franceschini; Fabio Pizza; Francesca Cavalli; Giuseppe Plazzi
Journal:  Neurotherapeutics       Date:  2021-04-22       Impact factor: 7.620

9.  Intermediate hypocretin-1 cerebrospinal fluid levels and typical cataplexy: their significance in the diagnosis of narcolepsy type 1.

Authors:  Adrienne Elisabeth van der Hoeven; Rolf Fronczek; Mink Sebastian Schinkelshoek; Frederik Willem Cornelis Roelandse; Jaap Adriaan Bakker; Sebastiaan Overeem; Denise Bijlenga; Gert Jan Lammers
Journal:  Sleep       Date:  2022-03-07       Impact factor: 6.313

10.  A Mobile App for Longterm Monitoring of Narcolepsy Symptoms: Design, Development, and Evaluation.

Authors:  Laury Quaedackers; Jan De Wit; Sigrid Pillen; Merel Van Gilst; Nikolaos Batalas; Gert Jan Lammers; Panos Markopoulos; Sebastiaan Overeem
Journal:  JMIR Mhealth Uhealth       Date:  2020-01-07       Impact factor: 4.773

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.